Baxter International Inc. (NYSE:BAX) Director Carole J. Shapazian sold 4,020 shares of Baxter International stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $61.61, for a total transaction of $247,672.20. Following the sale, the director now owns 13,868 shares in the company, valued at $854,407.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Baxter International Inc. (NYSE BAX) remained flat at $61.51 during midday trading on Friday. The stock had a trading volume of 2,389,377 shares. The stock has a market capitalization of $33.51 billion, a price-to-earnings ratio of 37.32 and a beta of 0.66. The stock has a 50-day moving average price of $61.00 and a 200 day moving average price of $56.25. Baxter International Inc. has a one year low of $43.13 and a one year high of $63.14.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.06. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The firm had revenue of $2.61 billion for the quarter, compared to analyst estimates of $2.59 billion. During the same quarter in the previous year, the company posted $0.46 EPS. The business’s revenue was up .8% on a year-over-year basis. Equities analysts predict that Baxter International Inc. will post $2.39 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 2nd. Shareholders of record on Friday, September 1st will be given a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, August 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.04%. Baxter International’s dividend payout ratio (DPR) is presently 38.79%.

WARNING: “Carole J. Shapazian Sells 4,020 Shares of Baxter International Inc. (BAX) Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/25/carole-j-shapazian-sells-4020-shares-of-baxter-international-inc-bax-stock.html.

Several large investors have recently made changes to their positions in BAX. Dumont & Blake Investment Advisors LLC raised its stake in shares of Baxter International by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 12,786 shares of the medical instruments supplier’s stock valued at $663,000 after buying an additional 40 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of Baxter International by 0.5% in the second quarter. Alps Advisors Inc. now owns 10,261 shares of the medical instruments supplier’s stock valued at $621,000 after buying an additional 52 shares during the last quarter. Livingston Group Asset Management CO operating as Southport Capital Management raised its stake in shares of Baxter International by 0.3% in the first quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 18,079 shares of the medical instruments supplier’s stock valued at $938,000 after buying an additional 54 shares during the last quarter. Clifford Swan Investment Counsel LLC raised its stake in shares of Baxter International by 0.4% in the first quarter. Clifford Swan Investment Counsel LLC now owns 15,204 shares of the medical instruments supplier’s stock valued at $788,000 after buying an additional 67 shares during the last quarter. Finally, Arrow Financial Corp raised its stake in shares of Baxter International by 2.6% in the first quarter. Arrow Financial Corp now owns 3,820 shares of the medical instruments supplier’s stock valued at $198,000 after buying an additional 95 shares during the last quarter. Institutional investors own 84.29% of the company’s stock.

BAX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “strong-buy” rating and set a $64.00 price objective on the stock in a research note on Monday, May 1st. UBS AG lifted their price objective on shares of Baxter International from $57.00 to $62.00 and gave the company a “neutral” rating in a research note on Friday, July 28th. Morgan Stanley lifted their price objective on shares of Baxter International from $48.00 to $52.00 and gave the company an “underweight” rating in a research note on Friday, April 28th. Goldman Sachs Group, Inc. (The) restated a “conviction-buy” rating and set a $71.00 price objective on shares of Baxter International in a research note on Tuesday, May 16th. Finally, Barclays PLC lifted their price objective on shares of Baxter International from $64.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Baxter International currently has a consensus rating of “Buy” and a consensus price target of $65.15.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Stock Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related stocks with our FREE daily email newsletter.